MaryCBirminghamMD

Emergency Medicine • Bronx, NY

Assistant Professor, Pediatrics, Weill Cornell Medical College

Join to view full profile

Are you Dr. Birmingham?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 40 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1400 Pelham Pkwy S
Bronx, NY 10461
Phone+1 718-918-5875
Is this information wrong?

Summary

Dr. Mary Birmingham, MD is an emergency medicine physician in Bronx, New York. She is currently licensed to practice medicine in New York, New Jersey, and Connecticut. She is affiliated with New York-Presbyterian Hospital and NewYork-Presbyterian/Lower Manhattan Hospital.

Education & Training

Montefiore Medical Center/Albert Einstein College of MedicineFellowship, Pediatric Emergency Medicine (Pediatrics), 2005 - 2008
Yale-New Haven Medical CenterResidency, Pediatrics, 1999 - 2002
Icahn School of Medicine at Mount SinaiClass of 1999

Certifications & Licensure

NJ State Medical License 2015 - 2025
NY State Medical License 2005 - 2024
CT State Medical License 2002 - 2005
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Emergency Medicine

Publications & Presentations

PubMed

13 citations
Screening for postpartum depression in a pediatric emergency department.
Mary C. Birmingham, Katherine J. Chou, Ellen F. Crain> ;Pediatric Emergency Care. 2011 Sep 1
14 citations
Neck pain and stiffness in a toddler with history of button battery ingestion.
Audrey Tan, Sigrid Wolfram, Mary Birmingham, Nathaniel Dayes, Eugene Garrow, Shahriar Zehtabchi> ;The Journal of Emergency Medicine. 2011 Aug 1
91 citations
Linezolid in the treatment of osteomyelitis: results of compassionate use experience.
Craig R Rayner, Larry M. Baddour, Mary C. Birmingham, Carl W. Norden, Alan K Meagher, Jerome J. Schentag> ;Infection. 2004 Feb 1
548 citations
Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections
Pamela A. Moise-Broder, Alan Forrest, Mary C. Birmingham, Jerome J. Schentag> ;Clinical Pharmacokinetics. 2004 Jan 1
56 citations
Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia
Patrick F. Smith, Mary C. Birmingham, Gary A. Noskin, Alison K. Meagher, Alan Forrest, Craig R Rayner, Jerome J. Schentag> ;Annals of Oncology. 2003 May 1
127 citations
Population Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program
Alison K. Meagher, Alan Forrest, Craig R Rayner, Mary C. Birmingham, Jerome J. Schentag> ;Antimicrobial Agents and Chemotherapy. 2003 Feb 1
155 citations
Clinical experience with linezolid for the treatment of nocardia infection.
Edina Moylett, Susan E. Pacheco, Barbara A. Brown-Elliott, Tracy R. Perry, E. Stephen Buescher, Mary C. Birmingham, Jerome J. Schentag, Joseph F. Gimbel, Aaron A. Apod...> ;Clinical Infectious Diseases. 2003 Feb 1
292 citations
Linezolid for the Treatment of Multidrug-Resistant, Gram-Positive Infections: Experience from a Compassionate-Use Program
Mary C. Birmingham, Craig R. Rayner, Alison K. Meagher, Susan M. Flavin, Donald H. Batts, Jerome J. Schentag> ;Clinical Infectious Diseases. 2003 Jan 15
233 citations
Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use Programme
Craig R Rayner, Alan Forrest, Alison K. Meagher, Mary C. Birmingham, Jerome J. Schentag> ;Clinical Pharmacokinetics. 2003 Jan 1
71 citations
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respo...
Pamela A. Moise, Alan Forrest, Mary C. Birmingham, Jerome J. Schentag> ;The Journal of Antimicrobial Chemotherapy. 2002 Dec 1
111 citations
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus
Pamela A. Moise, Alan Forrest, Sujata M. Bhavnani, Mary C. Birmingham, Jerome J. Schentag> ;American Journal of Health-System Pharmacy. 2000 Oct 1
171 citations
E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: A randomized controlled trial
Derek C. Angus, Mary C. Birmingham, Robert A. Balk, Patrick J. Scannon, David A. Collins, James A. Kruse, Donald R. Graham, Harakh V. Dedhia, Scott R. Homann, Neil R. ...> ;JAMA. 2000 Apr 5
24 citations
Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose
Mary C. Birmingham, Ross L. Guarino, Allen H. Heller, John H. Wilton, Anita Shah, Linda G. Hejmanowski, David E. Nix, Jerome J. Schentag> ;The Journal of Antimicrobial Chemotherapy. 1999 Mar 1
16 citations
ASSESSING ANTIBACTERIAL PHARMACOECONOMICS IN THE INTENSIVE CARE UNIT
Mary C. Birmingham, James M. Hassett, Jerome J. Schentag, Joseph A. Paladino> ;Pharmacoeconomics. 1997 Dec 1
20 citations
In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoidi...
Jerome J. Schentag, Mary C. Birmingham, J. A. Paladino, J. R. Carr, Judith M. Hyatt, A. Forrest, G. S. Zimmer, Martin H. Adelman, Thomas J. Cumbo> ;Seminars in Respiratory Infections. 1997 Dec 1
16 citations
Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems.
Jerome J. Schentag, Joseph A. Paladino, Mary C. Birmingham, Gabrial S. Zimmer, James R. Carr, Stephen C. Hanson> ;The Journal of Pharmacy Technology. 1995 Sep 1
48 citations
Mathematical Examination of Dual Individualization Principles (II): The Rate of Bacterial Eradication at the Same Area under the Inhibitory Curve is More Rapid for Cip...
Thomas F. Goss, Alan Forrest, David E. Nix, Charles H. Ballow, Mary C. Birmingham, Thomas J. Cumbo, Jerome J. Schentag> ;The Annals of Pharmacotherapy. 1994 Jul 1
The development of a bedside algorithm capable of targeting anti-endotoxins to the responder subpopulations
Mary C. Birmingham, David E. Nix, Thomas J. Cumbo, David A. Collins, Philip B. Wels, Jerome J. Schentag> ;Therapeutic Drug Monitoring. 1993 Dec 1
109 citations
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.
Alan Forrest, C H Ballow, David E. Nix, M C Birmingham, Jerome J. Schentag> ;Antimicrobial Agents and Chemotherapy. 1993 May 1
855 citations
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
Alan Forrest, David E. Nix, C H Ballow, T F Goss, M C Birmingham, Jerome J. Schentag> ;Antimicrobial Agents and Chemotherapy. 1993 May 1
Changing the infection control paradigm from off-line to real time: the experience at Millard Fillmore Health System.
Carr, J. R., Fitzpatrick, P., Izzo, J. L., Cumbo, T. J., Birmingham, M. C., Adelman, M. H., Paladino, J. A., Hanson, S. C., Schentag, J. J.> ;Infect Control Hosp Epidemiol. 1997 Apr
Pharmacokinetics and metabolism of moxifloxacin.
Moise, P. A., Birmingham, M. C., Schentag, J. J.> ;Drugs Today. 2000 Apr
Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the imp...
Schentag, J. J., Hyatt, J. M., Carr, J. R., Paladino, J. A., Birmingham, M. C., Zimmer, G. S., Cumbo, T. J.> ;Clin Infect Dis. 1998 May
Join now to see all

Hospital Affiliations

New York-Presbyterian HospitalNew York, New York
NewYork-Presbyterian/Lower Manhattan HospitalNew York, New York